Sell side status update - few years post Mifid, one year post Covid, etc

I w ould love to get an overall discussion on how people in the business (and outside of the business) view ER a few years after the adoption of Mifid, after last year's Covid boom in equity trading, the current issuance boom, etc. My gut is that the outlook for equity research as an industry/job opportunity has improved compared to say three years ago. Bonus pools seemed to increase this year, there is a lot of deal flow and the need for analysts.

I can also answer questions for anyone. I am a sector analyst with a team now (think Executive Director / Director level, so between VP and MD). 

35 Comments
 

any particular sector you're passionate about? Seats are opening up, jump on the opportunity while it's hot. Also happy to talk about how i broke in from with a non-traditional background

Go all the way
 
Most Helpful

I don't have all of the levels, I am not as close to comp for those the first few years in the industry. Bonus pools seemed to be up in the mid to high single digits this year, with a firm or two increasing pools in the low teens. New analysts with sector coverage responsibility seem to start at ~350K to over 500K depending on the sector; hotter sectors (internet, biotech, etc) seem to start higher. As you know, which coverage analysts, pay can vary widely. Top analysts in important sectors can get into the high six figures, with a few superstars here or there getting into 7 figures (though less than were used to be several years ago, or so I'm told). Associates with a few years experience and an associate corporate title seem to get base in the mid 100s with bonuses that can range from 50K or more (total comp in the 2s). VPs slightly higher. 

Firms that are known to pay aggressively for senior analysts include Wolfe. 

 

I interned in ER a few years ago and my 2 cents are: 

- there was an initial nervousness around MIFID II impact to ER careers

- majority of individuals I worked with during my brief stint moved to adjacent industries (buyside, IB, consulting). A senior member of my current team joined from ER at at a senior level for IB due to uncertainty re long-term impact to the industry

- our ER subscriptions, in terms of # of providers, has decreased but we place more reliance and speak more frequently to our highest quality providers who we continue to subscribe to. My inference would be (as an outsider) overall fee pool has decreased but still a significant opportunity for the highest quality shops

- a number of firms which ceased coverage of various sectors / verticals are resuming / initiating coverage as the market never completely dried up as some previously predicted

 

What's true:

-leaner teams + less resources + WFH = more hours and the perceived better work/life balance is not as true anymore

-there is some consolidation...Wells Fargo had a significant layoff last year (including some very talented people) and most firms are on a flat/down trajectory on headcount rather than hiring.

-data-driven work  is a bigger slice of product than fundamental research (though few traditional SS shops do data consistently well)

What's false:

-AI/automated programs are replacing research analysts..absolutely not the case and will not be for some time. 

-Buy-side firms are broadly insourcing more research functions (this is partially true at some leading shops, but not overall)

-compensation is down in recent years 

 

Ullam amet nihil similique sed repellendus. Qui perspiciatis enim laborum impedit. Similique architecto dolorum quia corrupti rerum. Vel sit nemo odio rerum aut.

Veniam commodi ipsa odio nostrum fuga. Velit dolorem consequuntur sed et aperiam provident. Atque voluptatem voluptatem beatae impedit exercitationem delectus. Eveniet illo nisi eos consectetur.

Unde culpa animi soluta quo. Sit repellendus ut cumque eius in dicta magnam. Odit odio quis magnam ullam odit hic dolorem adipisci. Asperiores error alias eum. Quia voluptatum sit eius eum et sed non. Libero officia suscipit cupiditate fuga impedit voluptatem.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.2%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.3%
  • Banco Santander 02 97.7%
  • BMO Capital Markets 12 97.2%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.2%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (16) $429
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
dosk17's picture
dosk17
98.9
6
GameTheory's picture
GameTheory
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
CompBanker's picture
CompBanker
98.9
9
DrApeman's picture
DrApeman
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”